Vantage Biosciences Australia

Vantage Biosciences is a clinical-stage biotechnology company focused on developing oral therapies for inflammatory diseases, specifically targeting diabetic eye conditions. Founded by ALSA Ventures and led by industry veteran Alek Safarian, the company is advancing its lead candidate, VX-01, which is a highly selective oral small molecule inhibitor of Amine Oxidase Copper-containing 3 (AOC-3). VX-01 is designed to address the neuroinflammatory root causes of non-proliferative diabetic retinopathy (NPDR) by preventing leukocyte trafficking and oxidative stress in the neurovascular unit of the eye. Currently in Phase 2 clinical trials, VX-01 represents a potential paradigm shift as a non-invasive, early-intervention alternative to the standard-of-care intravitreal injections. The company maintains a strong presence in Australia through its subsidiary, Vantage Biosciences Australia, which supports its global clinical development programs.